V. Rustgi

703 total citations
10 papers, 129 citations indexed

About

V. Rustgi is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, V. Rustgi has authored 10 papers receiving a total of 129 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hepatology, 3 papers in Epidemiology and 3 papers in Rheumatology. Recurrent topics in V. Rustgi's work include Hepatitis C virus research (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Liver Disease Diagnosis and Treatment (2 papers). V. Rustgi is often cited by papers focused on Hepatitis C virus research (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Liver Disease Diagnosis and Treatment (2 papers). V. Rustgi collaborates with scholars based in United States, Germany and Switzerland. V. Rustgi's co-authors include Anja Bondke Persson, Claudia Martorell, David Gardiner, Robert Reindollar, Timothy Eley, Dessislava I. Dimitrova, Mark Sulkowski, Anna S. Lok, Megan Wind‐Rotolo and Tao Guo and has published in prestigious journals such as Hepatology, Journal of Hepatology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

V. Rustgi

10 papers receiving 122 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Rustgi United States 6 101 91 25 24 21 10 129
Izumi Tsunematsu Japan 5 43 0.4× 31 0.3× 11 0.4× 18 0.8× 10 0.5× 6 68
Michel Blé Spain 5 56 0.6× 67 0.7× 18 0.7× 18 0.8× 4 0.2× 6 83
Г. В. Волынец Russia 7 23 0.2× 42 0.5× 24 1.0× 22 0.9× 7 0.3× 57 109
Doina Istrătescu Romania 5 32 0.3× 45 0.5× 18 0.7× 10 0.4× 13 0.6× 18 87
Floris F. van den Brand Netherlands 4 65 0.6× 68 0.7× 3 0.1× 30 1.3× 6 0.3× 8 101
Adriana Moţoc Romania 4 54 0.5× 60 0.7× 5 0.2× 19 0.8× 11 0.5× 10 98
James Markowitz United States 4 18 0.2× 66 0.7× 55 2.2× 26 1.1× 56 2.7× 15 108
Tien Huey Lim New Zealand 8 110 1.1× 131 1.4× 6 0.2× 43 1.8× 20 1.0× 12 186
E. Lorefice Italy 2 178 1.8× 215 2.4× 2 0.1× 15 0.6× 16 0.8× 3 225
Shifteh Abedian Iran 5 95 0.9× 114 1.3× 7 0.3× 19 0.8× 5 0.2× 9 134

Countries citing papers authored by V. Rustgi

Since Specialization
Citations

This map shows the geographic impact of V. Rustgi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Rustgi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Rustgi more than expected).

Fields of papers citing papers by V. Rustgi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Rustgi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Rustgi. The network helps show where V. Rustgi may publish in the future.

Co-authorship network of co-authors of V. Rustgi

This figure shows the co-authorship network connecting the top 25 collaborators of V. Rustgi. A scholar is included among the top collaborators of V. Rustgi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Rustgi. V. Rustgi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Lok, Anna S., David Gardiner, Eric Lawitz, et al.. (2011). 1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS. Journal of Hepatology. 54. S536–S536. 48 indexed citations
2.
3.
Nelson, David R., Reem Ghalib, Mark Sulkowski, et al.. (2009). 95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS. Journal of Hepatology. 50. S40–S40. 19 indexed citations
4.
5.
Rustgi, V., Vijayan Balan, Mark Sulkowski, et al.. (2006). 113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection. Journal of Hepatology. 44. S50–S50. 13 indexed citations
6.
Ahmed, Faroque, et al.. (2003). 1195 Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial. Hepatology. 38. 734–734. 1 indexed citations
7.
Bisceglie, Adrian M. Di, David Bernstein, V. Rustgi, et al.. (2001). Pegylated (40 KDA) interferon alfa-2a (PEGASYS®) in new combination therapies: a report of a randomized, multicenter efficacy and safety study. Journal of Hepatology. 34. 143–143. 9 indexed citations
8.
Manns, M.P., et al.. (2001). Pegylated interferon alpha 2b (PEG IFN) plus ribavirin (R) for treatment of chronic hepatitis C: optimization of ribavirin dose. Journal of Hepatology. 34. 236–236. 1 indexed citations
9.
Pockros, Paul J., J. McHutchison, Myron J. Tong, et al.. (2001). A phase II randomized, double-blind, placebo-controlled, multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin. 2. 350. 1 indexed citations
10.
Robinson, Malcolm, Dennis L. Decktor, Paul N. Maton, et al.. (1993). Omeprazole is superior to ranitidine plus metoclopramide in the short‐term treatment of erosive oesophagitis. Alimentary Pharmacology & Therapeutics. 7(1). 67–73. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Izumi Tsunematsu Breakdown of academic impact, for papers by Michel Blé Breakdown of academic impact, for papers by Г. В. Волынец Breakdown of academic impact, for papers by Doina Istrătescu Breakdown of academic impact, for papers by Floris F. van den Brand Breakdown of academic impact, for papers by Adriana Moţoc Breakdown of academic impact, for papers by James Markowitz Breakdown of academic impact, for papers by Tien Huey Lim Breakdown of academic impact, for papers by E. Lorefice Breakdown of academic impact, for papers by Shifteh Abedian
Rankless by CCL
2026